Core Insights - The company reported a revenue of RMB 3.181 billion for the six months ending June 30, 2025, representing a year-on-year increase of 3.46% [1] - The profit attributable to the parent company was RMB 313 million, a decrease of 19.33% year-on-year, with earnings per share at 8.32 cents [1] - The company maintains a competitive position in four major therapeutic areas in the Chinese market: oncology, central nervous system, cardiovascular, and metabolism [1] Revenue Breakdown - Revenue from the oncology segment increased by 13.5% to RMB 1.295 billion [2] - Revenue from the central nervous system segment rose by 5.4% to RMB 868 million [2] - Revenue from the cardiovascular segment decreased by 9.2% to RMB 693 million [2] - Revenue from the metabolism segment declined by 7.9% to RMB 180 million [2] Product Portfolio - The company's main product portfolio in China includes six oncology drugs, five central nervous system drugs, three cardiovascular drugs, and two metabolism drugs [1] - In the international market, the company's products are primarily focused on the central nervous system treatment area [1]
绿叶制药发布中期业绩，股东应占溢利3.13亿元 同比减少19.33%